Kaixin Auto Holdings Announces Change to its Board Members

BEIJING, April 07, 2020 (GLOBE NEWSWIRE) — Kaixin Auto Holdings (“Kaixin” or the “Company”) (NASDAQ: KXIN), one of the primary dealership networks in the premium used car segment in China, today announced that Sing Wang, has resigned from Kaixin’s board of directors, effective April 1, 2020, in order to focus on other business obligations.

Mr. Wang has served as chairman of the Nominating and Corporate Governance Committee and a member of the Audit Committee since Kaixin Auto Group consummated its business combination with CM Seven Star Acquisition Corporation through a share exchange, on April 30, 2019.

“On behalf of my fellow directors, the Company’s management team, and shareholders, I’d like to thank Sing for the significant contributions he made during his service on Kaixin’s Board,” said Mr. Joseph Chen, chairman of Kaixin. “Sing’s financial acumen and experience with complex corporate restructuring efforts brought invaluable insight to our organization during the Company’s formation, and the last twelve months of productive operation. We wish him the best in his future endeavors.”

About Kaixin Auto Holdings

Kaixin Auto Holdings is one of the primary dealership networks in the premium used car segment in China. Supported by the rapid growth of China’s used car market and leveraging its own hybrid business model that offers both strong online and offline presence, Kaixin has transformed from a tech-enabled financing platform into a nationwide dealer network that combines its own and affiliated dealers as well as value-added and after-sale services.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, the business outlook for the third quarter of 2019 and quotations from management in this announcement, as well as Kaixin’s strategic and operational plans, contain forward-looking statements. Kaixin may also make written or oral forward-looking statements in its filings with the U.S. Securities and Exchange Commission (“SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Kaixin’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: our goals and strategies; our future business development, financial condition and results of operations; the expected growth of the social networking site market in China; our expectations regarding demand for and market acceptance of our services; our expectations regarding the retention and strengthening of our relationships with used auto dealerships; our plans to enhance user experience, infrastructure and service offerings; competition in our industry in China; and relevant government policies and regulations relating to our industry. Further information regarding these and other risks is included in our other documents filed with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and Kaixin does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please contact:

Kaixin Auto Holdings

Randall Xu
Tel: +86 (10) 8448-1818 
Email: Randall.xu@renren-inc.com

The Piacente Group, Inc.

Ross Warner
Tel: +86 (10) 6508-0677
Email: Kaixin@tpg-ir.com

Jason Finklestein
Tel: +1 (212) 481-2050
Email: Kaixin@tpg-ir.com

SOURCE: Kaixin Auto Holdings


USA Rare Earth Acquires U.S. Rare Earth Permanent Magnet Manufacturing Capability

Adds Critical Component to USA Rare Earth’s Domestic U.S. “Mine to Magnet” Strategy

Round Top project would supply critical minerals necessary for rare earth magnet production

Rare earth permanent magnets are widely used in electronics, automotive, aerospace/defense, and renewable energy

New York, NY, April 07, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — USA Rare Earth, LLC, the funding and development partner of the Round Top Heavy Rare Earth and Critical Minerals Project in West Texas, is pleased to announce that it has purchased the neodymium iron boron (NdFeB) permanent magnet manufacturing equipment formerly owned and operated in North Carolina by Hitachi Metals America, Ltd.

Demand for rare earth magnets is being driven by electric vehicles (electric motors and batteries), wind generators (direct drive generators), medical devices (personal “vital signs” monitors and medical imaging machines), smart phones, and aerospace/defense applications, where high-performance in extreme conditions is important.

The $14 billion-a-year rare earth magnet market is more than 60% controlled by China which, under Made in China 2025, is increasingly using rare earth magnets in finished and semi-finished products, as opposed to exporting the magnets. Industry sources estimate the global rare earth magnet market will nearly double by 2027.

The equipment purchased by USA Rare Earth should provide most of what is needed to re-establish rare earth magnet production in the U.S. and, with the addition of some readily-available components, can produce at least 2,000 tonnes annually of rare earth magnets.

At 2,000 tonnes per year, the USA Rare Earth Magnet Plant would produce approximately 17% of the current U.S. market, and would generate more than $140 million in annual sales (at 2019 prices). At present, no other NdFeB permanent magnet manufacturing plant is operational in the Americas.

USA Rare Earth will warehouse the equipment pending a decision about where to locate the new magnet operation, with the priority being good access to the Round Top Project, located in Texas. At the same time, USA Rare Earth plans to work with manufacturers of rare earth metals and alloys in order to convert the highly purified rare earth oxides from Round Top into magnets.

“Acquiring this capability is consistent with our mine-to-magnet strategy,” said Pini Althaus, CEO of USA Rare Earth.  “We did not want the United States to lose this key equipment, so when it became clear that was an imminent possibility, we moved quickly to ensure that this essential part of the critical minerals supply chain remains in the U.S. We have commenced discussions with the domestic U.S. electric vehicle and defense sectors to determine their needs and to work together to establish a domestic source of not only the raw materials from Round Top, but also the finished magnet product. We expect to partner with one or more groups that have expertise in rare earth magnet manufacturing.”

“Together with the critical materials contained in our Round Top project, coupled with our new processing plant and now the acquisition of the rare earth magnet manufacturing equipment, we have put into place the key building blocks for re-establishing a domestic critical minerals supply chain independent of China,” added Mr. Althaus.

This acquisition is complementary to the Company’s Round Top Project in West Texas, which it is developing with Texas Mineral Resources Corp. (OTCQB: TMRC), and its pilot processing facility located in Wheat Ridge, Colorado.  Round Top is rich in heavy rare earths, including dysprosium and terbium, which are required for NdFeB magnets.  USA Rare Earth plans to produce high-purity separated rare earth powders at Round Top that could support this newly-acquired magnet manufacturing capacity and create a secure, reliable domestic supply chain. Round Top is also projected to produce 10,000 tonnes of lithium a year directed at the electric vehicle battery market.

“Developing a full rare earth supply chain independent of China is essential for both the national economy and national security,” said General Paul Kern, US Army (ret.), Board member of USA Rare Earth. “This plant provides the relevant industries in the U.S. the possibility of purchasing U.S. manufactured permanent magnets, without the reliance on China for this key component. The importance of this acquisition should not be underestimated.”

In December, 2019 Reuters reported that, according to a government document seen by Reuters detailing the latest attempt to weaken China’s control over the rare earths sector, the U.S. military plans to stockpile rare earth magnets used in Javelin missiles and F-35 fighter jets. Reuters further reported that the Pentagon is seeking proposals to cache a six-month supply of neodymium iron boron magnets, which the document describes as being “a type of rare earth magnet essential to weapons manufacturing.”

Rare Earth Magnets

According to industry estimates, permanent magnets are a $21 billion-a-year global market split between high-performance magnets (70%) and lower performance ferrite magnets (30%) used in applications such as chargers for electrical devices and other applications where weight and performance are less important and operating conditions are less extreme.

At $13.8 billion, rare earth magnets dominate the high-performance magnet market, replacing aluminum-nickel-cobalt and samarium-cobalt technologies.  Industry sources project the global rare earth magnet market will expand by nearly 100% to $27.0 billion in 2027.

In 2019, the U.S. purchased approximately 12,000 metric tonnes of rare earth magnets at an average price of approximately $71,000 per tonne, according to industry estimates, representing 6% of the global rare earth magnet market.  Note that this does not include magnets in finished and semi-finished products that are imported – since the U.S. was approximately 23.6% of global GDP in 2019, total imports of magnets could be at least four times the magnet-only numbers.

If the U.S. merely maintains its current 6% share of the global market, annual purchases of rare earth magnets will increase by more than 7,000 tonnes by 2027, or an annual increase of more than 900 tonnes per year.

USA Rare Earth (NdFeB) Permanent Magnet Plant

In late 2011, Hitachi announced the phased construction of a state-of-the-art sintered rare earth magnet manufacturing facility, planning to spend up to $60 million over four years. However, following settlement of the rare earth trade dispute between China and Japan, Hitachi closed the plant in 2015 after less than two years of operation. The equipment purchased by USA Rare Earth provides most of what is needed to re-establish rare earth magnet production in the U.S. and, with the addition of some readily-available components, can produce at least 2,000 tonnes annually of rare earth magnets. The Company and its potential partners will develop a detailed business plan and budget.

At 2,000 tonnes per year, the USA Rare Earth Magnet Plant would produce approximately 17% of the current U.S. market, and would generate more than $140 million in annual sales at 2019 prices.  USA Rare Earth anticipates that the rare earth magnet plant will be constructed near to the Round Top Project which is serviced by existing roads, rail and power infrastructure and is near centers of technology and research universities, including El Paso, Austin, and San Antonio.

About USA Rare Earth, LLC

USA Rare Earth, LLC has an option to earn up to an 80% interest in the Round Top Heavy Rare Earth and Critical Minerals Project located in Hudspeth County, West Texas from Texas Mineral Resources Corp. (TMRC: OTCQB).  Round Top hosts a wide range of critical heavy rare earth elements, high-tech metals, including lithium, uranium and beryllium, and, based on the Preliminary Economic Assessment (effective date July 1, 2019) is projected to be among the lowest-cost rare earth projects in the world.  The Round Top Deposit hosts 16 of the 17 rare earth elements, plus other high-value tech minerals (including lithium) and is well located to serve the US internal demand. In excess of 60% of materials at Round Top will be used directly in green or renewable energy technologies. Round Top contains 13 of the 35 minerals deemed “critical” by the Department of the Interior and contains critical elements required by the United States, both for national defense and industry. For more information about USA Rare Earth, visit www.usarareearth.com

Company Contact:

USA Rare Earth LLC
Pini Althaus, Chief Executive Officer
Email: pini@usarareearth.com

Twitter: @USARareEarth


MONTREAL, April 07, 2020 (GLOBE NEWSWIRE) — Osisko Metals Incorporated (the “Company” or “Osisko Metals“) (TSX-V: OM; OTCQX: OMZNF; FRANKFURT: 0B51) wishes to announce that continues to advance the Preliminary Economic Assessment (“PEA”) for its wholly-owned Pine Point Project, slated for release in Q2 2020 in collaboration with BBA Inc., WSP, Tetra Tech and Golder Associates Inc. The Company is currently focused on project optimization including material sorting methodology trade-off studies.

The Company is following the guidelines and advice of the Public Health Agency of Canada as well as regulations from provincial and territorial governments with respect to the COVID-19 virus. All personnel have been safely working from home since March 16th.

The 2019-2020 Pine Point winter exploration campaign has concluded due to spring break-up and compliance with guidelines of the Public Health Agency of Canada. The exploration camp has been placed on care and maintenance following travel restrictions and will remain so for the foreseeable future. Results of the winter drill program are being processed and will be released as soon as possible. The Company will be able to rapidly restart exploration and environmental baseline work campaigns that are planned for this year, once restrictions are lifted.

Robert Wares, Executive Chairman & CEO, commented “Along with our consultants, we continue to diligently advance the PEA of Pine Point and will continue to develop the project throughout 2020. Current market conditions have temporarily reduced demand for base metals, but weak spot markets will result in further deterioration of the zinc supply chain in the longer term through new mine closures and suspended development projects. We believe that Osisko Metals and the Pine Point project are best positioned to leverage this future opportunity in the zinc markets.”

The Company also wishes to announce that Mr. Paul Dumas has stepped down from his position as Executive Vice President Finance and Director of the Company to devote his efforts on several private businesses. However, he will maintain a role as Special Consultant to the Company. Mr. Dumas was co-founder and CEO of the Company from 2008 to 2017 (previously named Bowmore Exploration Ltd) and since June 2017 was instrumental in the successful reorganization to create Osisko Metals. Mr Dumas was also key in the completion of over $75 million in financings as well as the successful negotiation of the repurchase of the Pine Point NSR, amongst other things. The Company would like to thank Mr. Dumas for his contributions over the years and wishes him well in his future endeavors.

About Osisko Metals

Osisko Metals Incorporated is a Canadian exploration and development company creating value in the base metal space with a focus on zinc mineral assets. The Company controls Canada’s two premier zinc mining camps. The Company’s flagship properties are: 1) the Pine Point Mining Camp (“PPMC”), located in the Northwest Territories, has an Inferred Mineral Resource of 52.4 Mt grading 4.64% zinc and 1.83% lead (6.47% ZnEq), making it the largest pit-constrained zinc deposit in Canada (please refer to the Technical Report filed on SEDAR December 23, 2019 for further information). The PPMC is located on the south shore of Great Slave Lake in the Northwest Territories, near infrastructure and paved highway access and with 100 kilometres of viable haulage roads already in place. In 2019-2020, the company will explore for additional mineral resources and continue advancing the overall project. 2) The Bathurst Mining Camp (“BMC”), located in northern New Brunswick, has Indicated Mineral Resources of 1.96 Mt grading 5.77% zinc, 2.38% lead, 0.22% copper and 68.9g/t silver (9.00% ZnEq) and Inferred Mineral Resources of 3.85 Mt grading 5.34% zinc, 1.49% lead, 0.32% copper and 47.7 g/t silver (7.96% ZnEq) in the Key Anacon and Gilmour South deposits. Please refer to the technical report entitled “NI 43-101 Maiden Resource Estimate for the Bathurst Mining Camp, New Brunswick, Canada” dated April 4, 2019 (with an effective date of February 20, 2019) which has been filed on SEDAR. In 2019-2020, the Company will continue to diligently develop and explore in order to confirm and grow both projects. The Company is also active in Quebec where it is testing multiple grass-roots base metal targets.

The mineral resources mentioned in this press release conform to NI 43-101 standards and were prepared by independent qualified persons, as defined by NI 43-101 guidelines. The above-mentioned mineral resources are not mineral reserves as they do not have demonstrated economic viability. The quantity and grade of the reported Inferred Mineral Resources are conceptual in nature and are estimated based on limited geological evidence and sampling. Geological evidence is sufficient to imply but not verify geological grade and/or quality of continuity. Zinc equivalency percentages are calculated using metal prices, forecasted metal recoveries, concentrate grades, transport costs, smelter payable metals and charges (see respective technical reports for details).

Mr. Robin Adair, P.Geo and Vice President Exploration of Osisko Metals, is the Qualified Person who has approved of the scientific and technical information contained in this news release.

For further information on this press release, visit www.osiskometals.com or contact:

Killian Charles
VP Corporate Development
Osisko Metals Incorporated
(514) 861-4441
Email: info@osiskometals.com

Cautionary Statement on Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation based on expectations, estimates and projections as at the date of this news release. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, capital and operating costs varying significantly from estimates; the preliminary nature of metallurgical test results; delays in obtaining or failures to obtain required governmental, environmental or other project approvals; uncertainties relating to the availability and costs of financing needed in the future; changes in equity markets; inflation; fluctuations in commodity prices; delays in the development of projects; the other risks involved in the mineral exploration and development industry; and those risks set out in the Company’s public documents filed on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

One Identity Offers Free Safeguard for Privileged Sessions to Support Critical Infrastructure Providers Transitioning to a Remote Workforce

  • One Identity Safeguard for Privileged Sessions will be offered to critical infrastructure organizations free of charge for six months  
  • The solution deploys quickly and mitigates risk of a security breach by monitoring and managing privileged access to an enterprise’s most critical systems

ALISO VIEJO, Calif., April 07, 2020 (GLOBE NEWSWIRE) — One Identity, a proven leader in identity-centered security, today announced that it is offering free use of One Identity Safeguard for Privileged Sessions for six months to all critical infrastructure providers.

As emergency services, public health organizations, utilities and other critical organizations rush to enable as many remote workers as possible, best practices for keeping users secure have understandably become an ongoing challenge. One Identity’s Safeguard for Privileged Sessions enables organizations to reduce risk by monitoring and managing privileged access without hindering productivity.

Any organization relies on privileged IT users to configure systems and perform vital functions so their enterprise stays up and running. If this privileged access is not controlled as it shifts to remote administration, organizations face heightened risk. Unmanaged privileged access opens the door to attackers who can leverage it to steal data or compromise systems.

To support essential businesses that are working through challenging IT transitions right now, One Identity’s Safeguard for Privileged Sessions will provide numerous benefits, which include:

  • Fast and Simple Remote Deployment: With a rapid appliance-based deployment and simplified traffic re-routing, One Identity Safeguard can have organizations recording and securing sessions in a matter of days without disrupting users.
  • Record and Monitor all Session Activity of Remote Admins, Vendors and Contractors: All session activity, down to the individual keystroke, mouse movement, and Windows viewed – is captured, indexed and stored in tamper-proof audit trails that can be viewed like a video and searched like a database.
  • Real-time Alerting and Blocking of Potential Attacks or Rogue Users: The solution monitors traffic in real-time and executes various actions if a certain pattern appears. In the case of detecting a suspicious user action, Safeguard can log the event, send an alert or immediately terminate the session.

“These are unprecedented times, and organizations across all industries are being pushed to adapt quickly with little guidance on how to do so, potentially leaving them vulnerable,” said David Earhart, president and general manager of One Identity. “At One Identity we want to support those critical infrastructure providers who are being asked to do so much right now, by providing them the privileged access management capabilities they need to keep their systems secure without getting in the way of their essential missions.” 

To learn more about this offering, visit: https://www.oneidentity.com/secure-remote-access-for-your-critical-infrastructure/.

About One Identity

One Identity, a Quest Software business, lets organizations achieve an identity-centric security strategy with a uniquely broad and integrated portfolio of identity management offerings including AD account lifecycle management, identity governance and administration and privileged access management.  One Identity empowers organizations to reach their full potential, unimpeded by security, yet safeguarded against threats.  One Identity and its approach is trusted by customers worldwide, where more than 7,500 organizations worldwide depend on One Identity solutions to manage more than 125 million identities, enhancing their agility and efficiency while securing access to their systems and data – on-prem, cloud or hybrid. For more information, visit http://www.oneidentity.com.

Media contacts

Andrea Ipolyi
One Identity Global PR
+36 1 398 6700

Molly Hanrahan
Highwire PR

CytoDyn Collaborating with U.K.’s Department of Health to Provide Emergency Access to Leronlimab for Severe and Critically Ill COVID-19 Patients

CEO Nader Pourhassan will appear on FOX Business Network on April 7 at 11:00 am PT to provide an update on the Company’s two COVID-19 clinical trials and 15 patients on EIND

VANCOUVER, Washington, April 07, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that it is collaborating with the U.K.’s Department of Health to provide emergency access to leronlimab, the Company’s investigational medicine for COVID-19.  The submission to Medicines and Healthcare Products Regulatory Agency (MHRA), an executive agency of the U.K. government sponsored by the Department of Health and Social Care, is expected to be made soon to include clinical trial sites in the U.K. Representatives from the U.K. are coordinating with CytoDyn’s full-service international clinical research organization, Amarex Clinical Research, to prepare the requisite clinical agreements and to prepare for timely delivery of leronlimab.

The FDA recently cleared the Company to initiate a Phase 2b/3 clinical trial for severe and critically ill COVID-19 patients for which enrollment is now underway. The Phase 2b/3 trial for severe and critically ill COVID-19 patients is for 390 patients, double blinded with 2:1 ratio (active drug to placebo ratio). Patients enrolled in this trial are expected to be administered leronlimab for two weeks with the primary endpoint being the mortality rate at 28 days and a secondary endpoint of mortality rate at 14 days. The Company will perform an interim analysis on the data from 50 patients.

CytoDyn has initiated enrollment in a Phase 2 randomized clinical trial for mild-to-moderate COVID-19 population in the U.S. and is enrolling in a Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 population.

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, “We are humbled by the outpouring of inquiries and requests for access to leronlimab and are working around the clock with our many partners to facilitate access to a potential therapeutic benefit for COVID-19 patients.” Pourhassan concluded that, ”We are working with our CRO partner, Amarex Clinical Research, to establish similar expanded access (emergency use) programs for leronlimab for the treatment of COVID-19 with other governmental regulatory authorities.  The Amarex team is leading the clinical trial management and conduct of both Phase 2 and Phase 2b/3 projects and has done an exceptional job leading our clinical development initiative for leronlimab for the treatment of COVID-19.”

Separately, Dr. Pourhassan will appear on Fox Business Network on April 7 at 11:00 am PT to provide a full update on the CytoDyn’s two clinical trials for COVID-19, a Phase 2 trial for those patients with mild-to-moderate indications and a Phase 2b/3 trial for severe and critically ill patients.  

About Coronavirus Disease 2019

SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. The origin of SARS-CoV-2 causing the COVID-19 disease is uncertain, and the virus is highly contagious. COVID-19 typically transmits person to person through respiratory droplets, commonly resulting from coughing, sneezing, and close personal contact. Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals. For confirmed COVID-19 infections, symptoms have included fever, cough, and shortness of breath. The symptoms of COVID-19 may appear in as few as two days or as long as 14 days after exposure. Clinical manifestations in patients have ranged from non-existent to severe and fatal. At this time, there are minimal treatment options for COVID-19.

About Leronlimab (PRO 140)

The FDA has granted a “Fast Track” designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. Leronlimab has completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.

In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019. 

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted “orphan drug” designation to leronlimab for the prevention of GvHD.

About CytoDyn

CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biologics License Application (BLA) in April of 2020 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at www.cytodyn.com.

Forward-Looking Statements 
This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict.  Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believes,” “hopes,” “intends,” “estimates,” “expects,” “projects,” “plans,” “anticipates” and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Company’s forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the sufficiency of the Company’s cash position, (ii) the Company’s ability to raise additional capital to fund its operations, (iii) the Company’s ability to meet its debt obligations, if any, (iv) the Company’s ability to enter into partnership or licensing arrangements with third parties, (v) the Company’s ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Company’s ability to achieve approval of a marketable product, (vii) the design, implementation and conduct of the Company’s clinical trials, (viii) the results of the Company’s clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Company’s products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Company’s control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.


Dave Gentry, CEO
RedChip Companies
Office: 1.800.RED.CHIP (733.2447)
Cell: 407.491.4498

Second annual Canadian Transplant Association Green Shirt Day in honour of Humboldt Broncos defenseman Logan Boulet encourages organ donation registration

LETHBRIDGE, Alberta, April 07, 2020 (GLOBE NEWSWIRE) — The second annual Green Shirt Day is today. The day encourages people across Canada to register as organ donors and tell their family their wishes. There is widespread enthusiasm from the organ transplant community, schools and workplaces to take part in Green Shirt Day, whose activities have moved on-line.

Using the hashtags #GreenShirtDay and #LoganBouletEffect, Canadians are posting videos and photos that share why organ donation matters to them, why they are registered organ donors and that they’ve told their family their wishes. Examples include:

  • Leonard Hodder is a living liver donor in the GTA who gave part of his liver to a stranger. He shares his thoughts on organ donation in this tweet.
  • Abbie in Ottawa is encouraging organ donation with this video.

“I encourage people to go on whichever social media they like to use, be it Twitter, Instagram, Facebook or Tik-Tok, and post that you’re a registered organ donor,” says Toby Boulet. “Put on a green shirt then take a picture or make a video. Just tell everyone you’re registered to be an organ donor, have told your family your wishes and be inspired.”

It is estimated that more than 100,000 Canadians registered as organ donors in the weeks following the Humboldt crash in 2018 that took Logan Boulet’s life and led to him being an organ donor, known as the Logan Boulet Effect. The next year, Green Shirt Day 2019 inspired another hundred thousand or more to take action.

Logan’s legacy reminds us how important it is for Canadians to talk with their family about their organ donation wishes. It’s suggested that for every person who registers their intent to donate, they speak with an average of four others about organ donation. That means that 100,000 new registrants equals approximately 400,000 conversations.

Get more background, key statistics, organ donation terminology (e.g. use “retrieve organs” not “harvest organs”), and digital assets from our media kit.

This year, we are pleased to introduce toolkits to support participation from schools, businesses, teams, clubs and organizations.

About Canadian Transplant Association Green Shirt Day

The Canada-wide Green Shirt Day was created to remember the victims and families of the tragic Humboldt Broncos bus crash in Saskatchewan in 2018. And, to continue Logan Boulet’s legacy by inspiring Canadians to register as organ donors and to talk to their families about their wishes.

On April 7, learning that he would not recover, Bernadine and Toby Boulet offered to donate their son, Logan Boulet’s, organs. They did so because Logan had registered as an organ donor and had spoken to his parents about his wishes. His generous final act inspired more than 100,000 donor registrations across Canada shortly thereafter, which became known as the Logan Boulet Effect.

Media contacts:

Brenda Brown
Canadian Transplant Association

Canadian Blood Services
Renee Horton

Paul St-Germain
National Communications Manager
The Kidney Foundation of Canada
514-369-4806 or 1-800-361-7494 ext. 240

Toby Boulet
1-403-331-0823, tobyboulet@shaw.ca

Increase in Remote Working and Coronavirus Related Threats Creating Perfect Storm of Security Challenges for Organizations, New Survey Finds

Check Point Software & Dimensional Research’s survey shows 71% of IT and security professionals globally report an increase in security threats and attacks since the Coronavirus outbreak started, as criminals seek to exploit the remote working explosion

SAN CARLOS, Calif., April 07, 2020 (GLOBE NEWSWIRE) —
Check Point® Software Technologies Ltd. (NASDAQ: CHKP), a leading provider of cybersecurity solutions globally, has today announced findings from a new survey, conducted by Dimensional Research, examining the Coronavirus pandemic’s impact on enterprise security. The findings show that the rapid changes to enterprise working practices, and broader concerns about the pandemic, are both being exploited by cybercriminals as they step up their attacks, generating a raft of new challenges for security professionals.

Key findings from the survey of 411 IT and security professionals globally are:

  • Coronavirus
    related attacks ramp up – 71% of security professionals reported an increase in security threats or attacks since the beginning of the Coronavirus outbreak. The leading threat cited was phishing attempts (cited by 55% or respondents), followed by malicious websites claiming to offer information or advice about the pandemic (32%), followed by increases in malware (28%) and ransomware (19%).
  • Challenges of managing remote working increase – 95% of respondents said they are facing added IT security challenges due to the spread of the Coronavirus. The three leading challenges were provision of secure remote access for employees (cited by 56%), the need for remote access scalable solutions (55%) and employees working from home were using shadow IT solutions – untested software, tools and services (47%).
  • Security concerns over the coming months – 61% of respondents were concerned about the security risks of having to make rapid changes to enable remote working, and 55% felt that remote access security needed improving. 49% are concerned about the need to scale-up endpoint security.

“Cybercriminals will always seek to capitalize on the latest trends to try and boost the success rates of attacks, and the Coronavirus pandemic has created a perfect storm of a global news event together with dramatic changes in working practices and the technologies used by organizations. This has meant a significant increase in the attack surface of many organizations, which is compromising their security postures,” said Rafi Kretchmer, Head of Product Marketing at Check Point.

“To ensure security and business continuity in this rapidly evolving situation, organizations need to protect themselves with a holistic, end-to-end security architecture. This means ensuring accessible and reliable connections between corporate networks and remote devices 24/7, promoting collaboration and productivity between teams, networks and offices, and deploying robust protection against advanced threats and cybercrime techniques at all points on the enterprise network fabric.”

The survey results reinforce Check Point’s recent findings that Coronavirus-related domains are 50% more likely to be malicious than other domains registered since January 2020, and indeed the average number of new domains registered in the three weeks from the end of February was almost 10 times more than the average number found in previous weeks. Similarly, Check Point’s researchers have uncovered several ‘Coronavirus specials’ advertised by hackers on the dark web, with ‘Covid-19’ or ‘coronavirus’ being used as discount codes for sales of out-of-the-box malware.

Check Point has a full range of security solutions that ensure best-in-class connectivity and security for remote working, allowing workforces to remain as productive as possible. These include Check Point’s Remote Access VPN Software, Endpoint Threat Prevention, Mobile Security and Mobile Secure Workspace all aim to take a practical approach towards securing remote workers. Check Point’s SandBlast Agent delivers complete endpoint threat prevention against zero-day attacks delivering a 100% block rate even for unknown threats with zero false positives.

The survey was conducted by Dimensional Research, with 411 respondents from organizations of 500+ employees globally.

For full details of Check Point’s solutions for securing remote workforces, visit: https://www.checkpoint.com/solutions/secure-remote-workforce-during-coronavirus/

Follow Check Point via:

Twitter: http://www.twitter.com/checkpointsw
Facebook: https://www.facebook.com/checkpointsoftware
Blog: http://blog.checkpoint.com
YouTube: http://www.youtube.com/user/CPGlobal
LinkedIn: https://www.linkedin.com/company/check-point-software-technologies

About Check Point Software Technologies Ltd.

Check Point Software Technologies Ltd. (www.checkpoint.com) is a leading provider of cyber security solutions to governments and corporate enterprises globally. Check Point’s solutions protect customers from 5th generation cyber-attacks with an industry leading catch rate of malware, ransomware and advanced targeted threats. Check Point offers a multilevel security architecture, “Infinity Total Protection with Gen V advanced threat prevention”, this combined product architecture defends an enterprise’s cloud, network and mobile devices. Check Point provides the most comprehensive and intuitive one point of control security management system. Check Point protects over 100,000 organizations of all sizes.

Emilie Beneitez Lefebvre Kip E. Meintzer
Check Point Software Technologies Check Point Software Technologies
press@checkpoint.com ir@checkpoint.com

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/b095017c-3737-4d9e-9cc1-9b7c37a09266

POINT Biopharma Announces Global Prostate Oncology Therapeutic Board of Advisors

-Leading clinical and scientific expertise join together-

TORONTO, April 07, 2020 (GLOBE NEWSWIRE) — POINT Biopharma Inc. is pleased to announce the formation of its global prostate oncology therapeutic advisory board. 

The Board, comprised of leading global experts in scientific discovery and clinical leadership, will provide guidance, product input, and thought leadership on oncology trends and radiopharmaceutical development.

“We are very pleased with the exceptional composition of the new Global Advisory Board,” stated Dr. Neil Fleshner, POINT Biopharma’s Chief Medical Officer.  “I am honored to partner with these leading innovators to help guide POINT and bring our innovation into clinical settings this year.”

The POINT Biopharma Global Advisory Board members include:

  • Dr. Kim Chi (Board Chair), Senior Research Scientist, Vancouver Prostate Centre Chief Medical Officer & Vice President, BC Cancer Medical Oncologist, BC Cancer Professor, Department of Medicine, University of British Columbia
  • Dr. Johannes Czernin, Chief, Ahmanson Translational Theranostics Division, Nuclear Medicine (UCLA Medical Center), Editor-in-Chief, The Journal of Nuclear Medicine
  • Dr. Ur Metser, Division Head, Molecular Imaging Princess Margaret Hospital, Professor, University of Toronto
  • Dr. Scott Tagawa, Medical Oncologist, Specialty in Genitourinary (GU) Oncology (Cornell), Associate Professor of Clinical Medicine & Urology at New York Presbyterian, Weill Cornell Medicine
  • Dr. Vikas Prasad, Deputy Director, Department of Nuclear Medicine, University Hospital of Ulm
  • Dr. Oliver Sartor, Associate Dean and Medical Director, Tulane Cancer Center, Tulane Medical School

Dr. Kim Chi, Advisory board chair adds, “I am looking forward to working on the development of POINT’s clinical program and bringing these innovative next generation products to my patients.”

About POINT Biopharma

POINT Biopharma is a globally focused radiopharmaceutical company with a growing portfolio of best in class radiopharmaceutical assets. POINT is combining a seasoned management team with strategic partnerships in radio-isotope supply, manufacturing technology and novel direct to patient targeting to revolutionize radiopharmaceutical drug development and commercialization. Working closely with its scientific advisors, the Company anticipates commencement of its clinical trial programs in 2020.

For Investor or Media Inquiries:
Michael Gottlieb, CPA
(647) 268-4160



THE WOODLANDS, Texas, April 07, 2020 (GLOBE NEWSWIRE) — Smart Sand, Inc. (NASDAQ: SND) (the “Company”) provided an update on the current market environment.

The recent decline in oil prices resulting from a combination of oversupply from Russia and Saudi Arabia and reduced demand related to the COVID-19 pandemic has led many exploration and production companies and oilfield service companies to announce plans to slow or stop well completions activity.  In response, Smart Sand has reduced its total capital expenditure budget by up to $20 million, including a significant reduction in its SmartSystems™ manufacturing plans.  The Company now estimates that full year 2020 capital expenditures will be approximately $5 million to $10 million. The Company also put in place several SG&A cost-cutting measures, including salary reductions of its executive management team between 15% and 20% and suspension of its variable cash compensation programs for all employees, which the Company expects will result in a savings of approximately 25% over 2019 levels.  

Prior to these unexpected events, the Company’s first quarter sales volumes were strong at approximately 757,000 tons, an increase of more than 60% over fourth quarter 2019 sales volumes of 462,000 tons.

Chuck Young, Founder and CEO stated, “In these uncertain times, we felt action was needed to minimize our costs to be able to effectively manage through what is expected to be an extended turbulent market environment. These cuts in capex and compensation, while difficult decisions, will help us manage our cash flow needs. Remember, this is why we took a measured approach to spending in the ups… so we can manage through the downs. Our principle operating philosophies haven’t changed. Now more than ever we will strive to live within our cash flow so we can continue to operate in this difficult market environment while maintaining a strong balance sheet. At our core, we remain committed to offering the highest quality products and the highest quality service while maintaining low leverage. With this strategy, we believe, as we always have, that we will ultimately prevail in any market.”

About Smart Sand:

Smart Sand is a fully integrated frac sand supply and services company, offering complete mine to wellsite proppant supply and logistics solutions to its customers. The Company produces low-cost, high quality Northern White frac sand and offers proppant logistics and wellsite storage solutions to customers through its in-basin transloading terminal and SmartSystems wellsite proppant storage capabilities. The Company provides products and services primarily to oil and natural gas exploration and production companies and oilfield service companies. For more information, please visit www.smartsand.com.


Josh Jayne
Phone: (281) 231-2660
Email: jjayne@smartsand.com

Lee Beckelman
Phone: (281) 231-2660
E-mail: lbeckelman@smartsand.com

Nozomi Networks and Deloitte Partner to Deliver IT, OT and IoT Security Services in EMEA

Relationship adds Nozomi Networks industrial strength OT and IoT visibility and threat detection capabilities to Deloitte’s portfolio of cyber risk solutions, including a Nozomi Networks managed security service across Deloitte’s Cyber Intelligence Centers in EMEA

SAN FRANCISCO, April 07, 2020 (GLOBE NEWSWIRE) — Deloitte’s EMEA Cybersphere Center, and Nozomi Networks Inc., the leader in OT and IoT security, today announced a partnership to address growing EMEA demand for managed security services and solutions designed to holistically address IT, OT and IoT cybersecurity requirements. Deloitte will offer Nozomi Networks’ advanced solutions for OT and IoT visibility, operations monitoring, and threat detection to customers in EMEA.

“With this partnership, our customers immediately gain access to OT and IoT network monitoring and threat detection that is fully supported by Deloitte’s cyber risk services,” said Nicola Esposito, Risk Advisory Partner at Deloitte Spain. “By partnering with Nozomi Networks, we are delivering complete IT, OT and IoT expertise and a superior solution for our most demanding clients. With more than 25 Deloitte engineers now trained and certified on Nozomi Networks technology, we are equipped to support custom deployments for our clients. Additionally, customers have the option to leverage Nozomi Networks solutions as part of a full suite of IT, OT and IoT security services now available through Deloitte’s Cyber Intelligence Centers in EMEA.”

“We are excited to team with Deloitte to help more organizations meet their requirements for critical OT cybersecurity solutions that integrate effectively with IT and IoT,” said Nozomi Networks CEO Edgard Capdevielle. “This partnership accelerates our joint efforts in EMEA to help protect business critical infrastructure.”

Recognized as the market leader in OT and IoT security in the latest Frost & Sullivan Radar report, Nozomi Networks is valued for superior operational visibility, advanced OT and IoT threat detection and strength across EMEA deployments. Nozomi Networks solutions support more than 2.6 million devices in more than 2,250 installations spanning energy, manufacturing, mining, transportation, utilities and critical infrastructure. Nozomi Networks products span IT, OT and IoT to automate the hard work of inventorying, visualizing and monitoring industrial control networks through the innovative use of artificial intelligence. Use cases stretch beyond cybersecurity, and include trouble shooting, asset management and predictive maintenance.

In an increasingly digital world, cyber brings new opportunities and threats. Deloitte’s Cyber Risk services help clients address those threats to build smarter, faster, more connected futures. As a leader in cyber strategy consulting and cyber intelligence in EMEA, Deloitte offers a fully customizable suite of cyber solutions and managed services. With a commitment to technological innovation and broad industry expertise, Deloitte’s global network provides insight and experience to face any scenario.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (“DTTL”), its global network of member firms, and their related entities (collectively, the “Deloitte organization”). DTTL (also referred to as “Deloitte Global”) and each of its member firms and related entities are legally separate and independent entities, which cannot obligate or bind each other in respect of third parties. DTTL and each DTTL member firm and related entity is liable only for its own acts and omissions, and not those of each other. DTTL does not provide services to clients. Please see www.deloitte.com/about to learn more.

Deloitte is a leading global provider of audit and assurance, consulting, financial advisory, risk advisory, tax and related services. Our global network of member firms and related entities in more than 150 countries and territories (collectively, the “Deloitte organization”) serves four out of five Fortune Global 500® companies. Learn how Deloitte’s approximately 312,000 people make an impact that matters at www.deloitte.com

About Nozomi Networks
Nozomi Networks is the leader in OT and IoT security and visibility. We accelerate digital transformation by unifying cybersecurity visibility for the largest critical infrastructure, energy, manufacturing, mining, transportation, building automation and other OT sites around the world. Our innovation and research make it possible to tackle escalating cyber risks through exceptional network visibility, threat detection and operational insight.

Press Contacts:

Luis Hernández
lhernandezmedrano@deloitte.es  – +34 669356720

Jil Backstrom
jil.backstrom@nozominetworks.com – 303.913.1650
Follow the Nozomi Networks Blog
Follow @nozominetworks on Twitter
Visit and follow the Nozomi Networks Corporate Page on LinkedIn